JPRN-UMIN000020366已完成未知
Considerations of recurrence prevention efficacy of gemcitabine for patients with resected pancreatic cancer - Considerations of recurrence prevention efficacy of gemcitabine for patients with resected pancreatic cancer
Second Department of Surgery, Wakayama Medical University0 个研究点目标入组 30 人开始时间: 2015年12月27日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1) Interstitial pneumonia or pulmonary fibrosis. (2) Patients who require systemic administration of the following agents during the study treatment period. 1.Corticosteroid 2.Immunosuppresant, Immunostimulant (3) Active infections. (4) Severe complication (heart failure, renal failure, liver failure, bleeding from digestive ulcer, ileus,and uncontrolled diabetes) (5) Pleural effusion, ascites fluid, or pericardial fluid in need of drainage. (6) Active double cancer (include asynchronous double cancer with disease-free duration <=3 year) except carcinoma in situ or intramucosal cancer. (7) Prior treatment of peptide derived from KIF20A, VEGFR-1and VEGFR-2. (8) Prior cancer treatment except for pancreatic cancer (chemotherapy, hormone therapy, antibody therapy, radiation therapy, immunotherapy, and hyperthermia). (9) Severe mental disorder. (10) Sever drug-induced hypersensitivity (11) Unhealed traumatic lesion, including traumatic fracture. (12) History of myocardial infarction, severe unstable angina pectoris, CABG, congestive heart failure, cerebrovascular accident, pulmonary embolism, deep-vein thrombosis, or other severe thromboembolism within 12 months before administration of OCV-C01. (13) Need continuous medication of antiplatelet drug except aspirin. (14) Uncontrolled hypertension. (15) Heart failure and arrhythmia that needs treatment. (16) Aneurysms and varices with serious concern of bleeding. (17) Current participation in other clinical trials. (18) Patients or partners, who don't attempt to doing contraception during the study period (during the study period and until 180 days after the last administration day for male, or until 120 days after the last administration day for female.). (19) Pregnant females or nursing mothers who can not stop lactation during the recruitment until 120 days after the last administration. (20) The subject who was determined by investigator that being not adequate to participate in the trial.
研究者
相似试验
已完成
不适用
Examination concerning utility of relapse prevention of factor and ursodeoxycholic acid related to relapse after total biliary stone is removedJPRN-UMIN000003732Hiroshima University hospital Department of General Internal Medicine360
已完成
不适用
Clinical study to investigate recurrence efficacy on a combined use of radiofrequency ablation therapy and auto-gamma/delta T cell therapy for hepatitis C virus-related hepatocellular carcinoma patients.Hepatitis C virus-related hepatocellular carcinomaJPRN-UMIN000004583Tokyo Medical University40
已完成
不适用
Efficacy of relapse prevention techniques and social skills training for juveniles who have sexually offendedISRCTN38356086Child and Adolescent Psychiatric Service, Canton of Zurich (Switzerland)120
招募中
不适用
The effect of follow-up prevention or these of heel pressure ulcer, drop foot, and pelvic rotation in patients coma or low alertness intensive care unit (ICU) Semnan kowsar hospitalheel pressure ulcer.Open wound of ankleS91.0IRCT20151228025732N45Semnan University of Medical Sciences60
已完成
不适用
The examination of prevention effect for reinjury in athlete after anterior cruciate ligament reconstruction(ACLR)anterior cruciate ligament injuryJPRN-UMIN000020297Waseda University15